Journal of Biosciences

, Volume 16, Issue 4, pp 223–233 | Cite as

Plasminogen activator: Isolation and purification from Lymphosarcoma of ascites bearing mice

  • M. W. Nulkar
  • Rukmini Darad
  • M. Subramanian
  • A. R. Pawse


Plasminogen activator secreted by lymphosarcoma (ascites) of mice was purified up to 163-fold by ammonium sulphate fractionation at 35% saturation and chromatography on p-aminobenzamidine-Sepharose 4B. The purified activator contained specific activity of 9980 IU/mg. The plasminogen activator displayed homogeneity by polyacrylamide slab gel electrophoresis and high performance liquid chromatography. The activator consisted of a single polypeptide chain with an apparent molecular weight of 66,000 daltons as determined by sodium dodecyl sulphate-polyacrylamide gel electrophoresis under reducing conditions as well as gel filtration on Sephadex G-100. Distinct differences between this activator and urokinase were discernible in respect of specific activities, fibrin affinity and immunochemical properties. The lymphosarcoma activator appears to be of tissue-type origin since it showed gross similarity to standard tissue plasminogen activator in terms of modes of binding to fibrin and immunological attributes.


Plasminogen activator urokinase fibrinolysis Fibrin lymphosarcoma 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Cajot J F, Kruithof E K O, Schleuning W D, Sordat B and Bachmann F 1986 Plasminogen activators, plasminogen activator inhibitors and procoagulant analysed in twenty human cell lines;Int. J. Cancer 38 719–727PubMedCrossRefGoogle Scholar
  2. Cheung A, Lau H K F and Yuen P 1986 A plasminogen activator from benign ovarian cystadenoma: Partial purification and characterization;Thromb. Res. 41 717–729PubMedCrossRefGoogle Scholar
  3. Collen D C and Gold H K 1990 New developments in thrombolytic therapy;Thromb. Res. Suppl. 10 105–131PubMedGoogle Scholar
  4. Collen D, Lijnen H R, Todd P A and Goa K L 1989 Tissue-type plasminogen activator: A review of its pharmacology and therapeutic use as a thrombolytic agent;Drug 38 346–388Google Scholar
  5. Dano K, Andreasen P A, Grondahl-Hansen J, Kristensen P, Nielsen L S and Skriver L 1985 Plasminogen activators, tissue degradation and cancer;Adv. Cancer Res. 44 139–266PubMedCrossRefGoogle Scholar
  6. Deutsch D G and Mertz E T 1970 Plasminogen: Purification from human plasma by affinity chromatography;Science 170 1095–1096PubMedCrossRefGoogle Scholar
  7. Dodd I, Jalalpour S, Southwick W, Newsome P, Browne M J and Robinson J H 1986 Large scale, rapid purification of recombinant tissue-type plasminogen activator;FEBSLett. 209 13–17CrossRefGoogle Scholar
  8. Einarsson M, Brandt J and Kaplan L 1985 Large scale purification of human tissue-type plasminogen activator using monoclonal antibodies;Biochim. Biophys. Acta 830 1–10PubMedGoogle Scholar
  9. Electricwala A, Ling R J, Sutton P M, Griffiths B, Riley P A and Atkinson T 1985In vitro studies on the fibrinolytic, thrombolytic and fibrinogenolytic properties of a tissue plasminogen activator from guinea pig keratocytes;Thromb. Haemostasis 53 200–203Google Scholar
  10. Gilbert L C and Wachsman J T 1982 Characterization and partial purification of the plasminogen activator from human neuroblastoma cell line, sk-n-sh;Biochim. Biophys. Acta 704 450–460PubMedGoogle Scholar
  11. Gross J L, Behrens D L, Mullins D E, Kornblith P L and Dexter D L 1988 Plasminogen activator and inhibitor activity in human glioma cells and modulation by sodium butyrate;Cancer Res. 48 291–296PubMedGoogle Scholar
  12. Hajjar K A and Hamel N M 1990 Identification and characterization of human endothelial cell membrane binding sites for tissue-plasminogen activators and urokinase;J. Biol. Chem. 265 2908–2916PubMedGoogle Scholar
  13. Hekman C M and Loskutoff D J 1987 Fibrinolytic pathways and endothelium;Semin. Thromb. Hemostasis 13 514–527CrossRefGoogle Scholar
  14. Hoal E G, Wilson E L and Dowdle E B 1983 The regulation of tissue-plasminogen activator activity by human fibroblasts;Cell 34 273–279PubMedCrossRefGoogle Scholar
  15. Johnson A J, Kline D J and Alkjaersig N 1969 Determination of caseinolytic activity for plasminogen activation;Thromb. Diath. Haemorrh. (Stuttg.) 21 259–272Google Scholar
  16. Katzenberger G J, Lea M A and Suriender Kumar 1987 Presence of urokinase like plasminogen activator in fast growing cells;Fed. Proc. 46 1963Google Scholar
  17. Katzenberger G J, Lea M A and Suriender Kumar 1988 Plasminogen activator activity of rat hepatomas;Fed. Am. Soc. Exp. Biol. 2 A388Google Scholar
  18. Kluft C, Van Wezel A L, Van der Velden CAM, Emeis J J, Verheijen J H and Wijngaards G 1983 The molecular form of α2-antiplasmin with affinity for plasmin is selectively bound to fibrin by factor XIII; inAdvances in biotechnological processes (eds) A Mizrahi and A L Van Wezel (New York: Alan RLiss)pp97–110Google Scholar
  19. Laemmli U K 1970 Cleavage of structural proteins during the assembly of the head of bacteriophage T4;Nature (London) 227 680–685CrossRefGoogle Scholar
  20. Loskutoff D J 1988 Type 1 plasminogen activator inhibitor and its potential influence on thrombolytic therapy;Semin. Thromb. Hemostasis 14 100–109Google Scholar
  21. Lowry O H, Rosebrough N J, Farr A L and Randall R J 1951 Protein measurement with the Folin phenol reagents;J. Biol. Chem. 193 265–275PubMedGoogle Scholar
  22. Lugtenberg B, Meijers J, Peter R, Vander Hock P and Van Alpem L 1975 Electrophoretic resolution on the major outer membrane protein ofE. coli K12 into four bands;FEBS Lett. 58 254–258PubMedCrossRefGoogle Scholar
  23. Nulkar M W, Chanderkar L P, Pawse A R and Nadkarni G B 1983 Possible methylation of plasma proteins involved in coagulation and fibrinolysis;Indian J. Biochem, Biophys. 20 338–343Google Scholar
  24. Nulkar M W and Pawse A R 1991 Isolation and purification of plasminogen activator from Yoshida ascites sarcoma of rats;Indian J. Biochem. Biophys. 28 46–51PubMedGoogle Scholar
  25. Ouchterlony O and Nilsson L A 1973Handbook of experimental immunology 2nd edition (ed.) D W Weir (Oxford: Black well) Chapter 19, pp 1–39Google Scholar
  26. Poduval T B, Seshadri M and Sundaram K 1984 Enhanced host resistance to transplantable murine lymphosarcoma in Swiss mice by combined immunostimulation with BCG and polyinolinic-polycytidylic acid;J. Natl. Cancer. Inst. 72 139–144PubMedGoogle Scholar
  27. Preger M D, Nelson N F, Cieplak W and Dacus S C 1986 Characterization of plasminogen activator from 2 human renal-carcinoma cell lines and efect of differentiation inducing agents;Proc. Am. Assoc. Cancer Res. 27 3Google Scholar
  28. Ranby M and Brandstrom A 1988 Biological control of tissue plasminogen activator-mediated fibronolysis;Enzyme 40 130–143PubMedGoogle Scholar
  29. Rijken D C and Collen D 1981 Purification and characterization of the plasminogen activator secreted by human melanoma cells in culture;J. Biol. Chem. 256 7035–7041PubMedGoogle Scholar
  30. Saksela O 1985 Plasminogen activation and regulation of pericellular proteolysis;Biochem. Biophys. Acta 823 35–65PubMedGoogle Scholar
  31. Thakur V S, Seshadri M, Poduval T B, Shah D H and Sundaram K 1990 Allosensitisation induced suppression of various murine tumors: Role of non-H-2 antigens in antitumour immunity;Indian J. Exp. Biol. 28 706–710PubMedGoogle Scholar
  32. Tozser J, Hamvas A, Rady P, Kertai P and Elodi P 1989 Plasminogen activator and plasminlike activities in experimental rat tumours;Acta Biochim. Biophys. Hung. 24 119–129PubMedGoogle Scholar
  33. Vansetten G B, Salonen E M, Vaheri A, Beuerman R W, Hietanen J, Tarkkanen A and Tervo T 1989 Plasmin and plasminogen activator activity in tear fluid during corneal wound healing after anterior keratectomy;Curr. Eye Res. 8 1293–1298Google Scholar
  34. Verstraete M 1990 Newer thrombolytic agents; inCardiology Update Reviews for Physicians (ed.) E. Rapaport (New York, Amsterdam, London: Elsevier) pp 99–111Google Scholar
  35. Wray W, Boulikas T, Wray V P and Hancock R 1981 Silver staining of proteins in polyacrylamide gels;Anal Biochem. 118 197–203PubMedCrossRefGoogle Scholar
  36. Wallen P, Pohl G, Bergsdorf N, Ranby M, Ny T and Jornvall H 1983 Purification and characterization of a melanoma cell plasminogen activator;Eur. J. Biochem. 132 681–686PubMedCrossRefGoogle Scholar

Copyright information

© Indian Academy of Sciences 1991

Authors and Affiliations

  • M. W. Nulkar
    • 1
  • Rukmini Darad
    • 1
  • M. Subramanian
    • 1
  • A. R. Pawse
    • 1
  1. 1.Biochemistry DivisionBhabha Atomic Research CentreBombayIndia

Personalised recommendations